News stories about Humana (NYSE:HUM) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Humana earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the insurance provider an impact score of 45.4219686204933 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Humana’s stock drops after downbeat PDP membership outlook (finance.yahoo.com)
- Humana Sees Relative Strength Rating Improve To 71 (finance.yahoo.com)
- Humana Inc. to Present at the 36th Annual JP Morgan Healthcare Conference – Digital Journal (digitaljournal.com)
- Humana Inc (HUM) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
- 4 Health Care Stocks Prescribed As Buys By Goldman Sachs (finance.yahoo.com)
Several equities research analysts recently issued reports on HUM shares. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $273.00 price objective on the stock in a report on Tuesday, October 3rd. Cowen reiterated a “buy” rating and issued a $285.00 price objective on shares of Humana in a report on Wednesday, December 13th. Goldman Sachs Group started coverage on Humana in a report on Wednesday, January 3rd. They issued a “buy” rating and a $305.00 price objective on the stock. Jefferies Group reiterated a “hold” rating and issued a $257.00 price objective on shares of Humana in a report on Friday, October 13th. Finally, Royal Bank of Canada reiterated a “hold” rating and issued a $245.00 price objective on shares of Humana in a report on Tuesday, October 10th. Twelve research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $258.62.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.27 by $0.12. Humana had a return on equity of 15.99% and a net margin of 3.49%. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $13.41 billion. During the same quarter in the prior year, the business earned $3.18 EPS. Humana’s revenue was down 3.0% on a year-over-year basis. analysts anticipate that Humana will post 11.63 EPS for the current year.
Humana announced that its Board of Directors has authorized a stock buyback program on Thursday, December 14th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the insurance provider to buy shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.
The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be issued a dividend of $0.40 per share. The ex-dividend date is Thursday, December 28th. This represents a $1.60 annualized dividend and a yield of 0.61%. Humana’s dividend payout ratio (DPR) is 12.60%.
In other news, SVP Brian P. Leclaire sold 1,679 shares of the stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $245.97, for a total value of $412,983.63. Following the transaction, the senior vice president now owns 9,888 shares in the company, valued at approximately $2,432,151.36. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Jody L. Bilney sold 7,054 shares of the stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $247.89, for a total value of $1,748,616.06. Following the completion of the transaction, the senior vice president now owns 11,704 shares in the company, valued at approximately $2,901,304.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,115 shares of company stock worth $2,501,627. 0.80% of the stock is owned by company insiders.
WARNING: “Humana (HUM) Earning Somewhat Positive Media Coverage, Study Finds” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.com-unik.info/2018/01/09/humana-hum-earning-somewhat-positive-media-coverage-study-finds.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.